Xi'an-Janssen Pharmaceutical Ltd.
Clinical trials sponsored by Xi'an-Janssen Pharmaceutical Ltd., explained in plain language.
Pharmaceutical company, a joint venture of Johnson & Johnson in China.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for Crohn's patients: study tests guselkumab after ustekinumab fails Results expected Sep 2027 (estimated)
-
New study tests biologic drug guselkumab for ulcerative colitis in chinese patients
Disease control Recruiting nowThis study follows 200 Chinese patients with moderate-to-severe ulcerative colitis who have never taken biologic drugs. They will receive guselkumab as part of their normal care. Researchers will measure changes in symptoms and quality of life over 48 weeks to see how well the dr…
Sponsor: Xian-Janssen Pharmaceutical Ltd. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New hope for Crohn's patients: study tests guselkumab after ustekinumab fails
Disease control Recruiting nowThis study tests whether guselkumab can help people with Crohn's disease whose current treatment (ustekinumab) has stopped working. Crohn's disease causes severe gut inflammation. About 78 Chinese adults with active Crohn's will receive guselkumab and be followed for 48 weeks to …
Phase 4 • Sponsor: Xian-Janssen Pharmaceutical Ltd. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC